{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26"}],"title":"Complete Response (CR1)"},{"measurements":[{"groupId":"OG000","value":"32"}],"title":"Very Good Partial Response (VGPR1)"},{"measurements":[{"groupId":"OG000","value":"7"}],"title":"Partial Response (PR1)"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"description":"Using IMWG criteria: PR (partial response) noted as \\>50% reduction of serum M-protein and reduction in 24hr urinary M-protein by \\>90% or to \\<200mg/24h; VgPR (very good partial response) noted as serum and urine M-protein detectable by immunofixation but not on electrophoresis or \\>90% reduction in serum M-protein plus urine M-protein level \\<100mg/24h; CR (complete response) noted as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow; sCR (stringent complete response) noted as CR defined above plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence.","groups":[{"description":"Bendaumustine, Etoposide, Cytrabine and Melphalan in autologous transplant for multiple myeloma\n\nBeEAM: BeEAM","id":"OG000","title":"BeEAM"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Day 100","title":"To Estimate the Response at Day 100 Following Transplant (Rate of CR)","type":"PRIMARY","unitOfMeasure":"Participants"}